| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/08/2008 | US7354903 For skin care; 5-23 amino acids in length and >/= 50% phenylalanine, leucine, alanine, and lysine residues; microbiocides, fungicides, and anticancer agents |
| 04/08/2008 | US7354902 Comprises nucleotide sequence coding genetically engineered transferrin for use in cosmetic and cancer diagnostics; antiinflammatory agents; viricides; bactericides |
| 04/08/2008 | US7354901 Production of recombinant BMP-2 |
| 04/08/2008 | US7354900 Also bactericidal or bacteriostatic contact lens coated with the peptide |
| 04/08/2008 | US7354899 Treating autoimmune diseases such as multiple sclerosis with CXCR4 antagonist such as peptides having of stromal cell derived factor one (SDF-1) sequences |
| 04/08/2008 | US7354898 Identifying agents which modify mitogen activated kinase activities associated with cell death; small interfering RNA and treament of cell proliferative disorders; for modulating diseases and conditions associated with elevated or decreased apoptosis |
| 04/08/2008 | US7354897 Providing a procoagulant membrane comprising a binding site containing phosphatidyl-L-serine; adding lactadherin to the membrane wherein the lactadherin will bind to the binding site and reduce access for interaction by a coagulation molecule |
| 04/08/2008 | US7354896 Suspension containing milk fat spheres; therapy for infant weight diseases |
| 04/08/2008 | US7354895 Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors |
| 04/08/2008 | US7354894 Administering epidermal growth factor receptor antagonist; blocking with monoclonal antibody, a kinase inhibitor, a metalloproteinase inhibitor; treating nasal polyps, chronic obstructive pulmonary disease |
| 04/08/2008 | US7354769 Comparing the ability of N,N-bis(3-D-gluconamidopropyl)-deoxycholamine to inhibit binding of IGFBP-1 or -3 to IGF-1 with the ability of a candidate indirect agonist of IGF-1 to identify effective agonists |
| 04/08/2008 | US7354761 Yeast cells; ribonuclease barnase marker gene; libraries; drug resistance |
| 04/08/2008 | US7354739 Modulation contraction of stomach tissue; gastrointestinal disorders; applying peptide |
| 04/08/2008 | US7354737 peptide delivers biological response modifiers into cytoplasm, intracellular organelles or nucleus of prokaryotic/eukaryotic cells; use in drug delivery, vaccines, gene and protein therapy |
| 04/08/2008 | US7354736 Intracellular caspase inhibitory polypeptide for use in treatment and prevention of cell proliferative, nervous system and autoimmune disorders |
| 04/08/2008 | US7354734 Leucine aminopeptidase polypeptide, carboxypeptidases polypeptide; dermatophyte; degradation of polypeptide substrate; Exonuclease X of Escherichia coli ( EXOX protein); fungicides; |
| 04/08/2008 | US7354728 Coactivation of nuclear receptors |
| 04/08/2008 | US7354724 Drosophila G protein coupled receptors, nucleic acids, and methods related to the same |
| 04/08/2008 | US7354709 Diagnosing cancer in mammals; obtain sample cells, monitor expression of collapsin protein, amplified concentration of collapsin indicates cancer |
| 04/08/2008 | US7354606 touchi plant extract and phaseolamin mixture for limiting the absorption of carbohydrates contained in a foodstuff, for promoting weight loss in an individual; nutraceuticals |
| 04/08/2008 | US7354592 Administering mutant Salmonella sp. for therapy of solid tumor cancer, disrupted msbB gene and is capable of targeting a solid tumor cancer |
| 04/08/2008 | US7354588 Organ transplantation, tissue grafting, allergy, oncology, diagnosis, therapy |
| 04/08/2008 | US7354586 Treating arthritis by administering a therapeutically effective amount of an antibody immunospecific for av beta 3; antiarthritic agents;anticarcinogenic agents; antitumor agents; antimetastasis agents; antiinflammatory agents; antibody does not immunoreact with integrins other than av beta 3 |
| 04/08/2008 | US7354585 Methods of treating coagulapathic or thrombotic disorders |
| 04/08/2008 | US7354583 Antibody-induced apoptosis |
| 04/08/2008 | US7354582 Use of VEGF antagonists for the treatment of malignant gliomas |
| 04/08/2008 | US7354581 For treating a disease or condition related to angiogenesis |
| 04/08/2008 | US7354580 Method of administering and using VEGF inhibitors for the treatment of human cancer |
| 04/08/2008 | US7354579 Method of treating cancer with a VEGF antagonist and an anti-proliferative agent |
| 04/08/2008 | US7354578 Method of tumor regression with VEGF inhibitors |
| 04/08/2008 | US7354576 Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidase |
| 04/08/2008 | US7354575 IFN- gamma interferons; side effect reduction |
| 04/08/2008 | US7354574 Treatment of ocular disease |
| 04/08/2008 | CA2349620C Use of aliphatic polyamines for reducing oxalate |
| 04/08/2008 | CA2295588C Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations |
| 04/08/2008 | CA2260909C Intestinal absorption of nicotine to treat nicotine responsive conditions |
| 04/08/2008 | CA2259632C A method for chromatographic removal of prions |
| 04/08/2008 | CA2169171C New growth/differentiation factor of the tgf-beta family |
| 04/08/2008 | CA2141953C Pharmaceutical formulations of interleukin-1 inhibitors |
| 04/08/2008 | CA2124967C Transgenic non-human animals capable of producing heterologous antibodies |
| 04/08/2008 | CA2122732C Multivalent antigen-binding proteins |
| 04/08/2008 | CA2111006C A novel receptor-type tyrosine kinase and use thereof |
| 04/03/2008 | WO2008039994A2 Targeted photodynamic therapy agent |
| 04/03/2008 | WO2008039983A2 Methods and compositions using mutant gp120 |
| 04/03/2008 | WO2008039909A1 Genetic modification of targeted regions of the cardiac conduction system |
| 04/03/2008 | WO2008039876A1 Cytokine signaling |
| 04/03/2008 | WO2008039863A2 Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders |
| 04/03/2008 | WO2008039843A2 Novel peptides that promote lipid efflux |
| 04/03/2008 | WO2008039818A2 Modified t cell receptors and related materials and methods |
| 04/03/2008 | WO2008039644A2 Compositions and methods for treating cancer |
| 04/03/2008 | WO2008039361A2 Method for enhancing immune responses in mammals |
| 04/03/2008 | WO2008039351A2 Method of manufacturing tablets containing pharmacologically active agents |
| 04/03/2008 | WO2008038777A1 Therapeutic agent for disseminated intravascular coagulation syndrome |
| 04/03/2008 | WO2008038644A1 Agent for preventing development of reflex sympathetic dystrophy after stroke |
| 04/03/2008 | WO2008038599A1 Axonal regeneration promoter |
| 04/03/2008 | WO2008038394A1 Musclin receptor and use thereof |
| 04/03/2008 | WO2008038138A1 Optimal method for recombinant production of a marine metalloprotein and uses thereof |
| 04/03/2008 | WO2008037720A2 Means and methods for diagnosing and/or treating a subject at risk of developing heart failure |
| 04/03/2008 | WO2008037666A1 Upar selective contrast agent for magnetic resonance imaging |
| 04/03/2008 | WO2008037497A2 Galectin-2 for the treatment of inflammatory diseases of the skin |
| 04/03/2008 | WO2008037449A2 Use of at least one isoform of progesterone receptor membrane component 1 (pgrmc1) |
| 04/03/2008 | WO2008037225A1 Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor |
| 04/03/2008 | WO2008037028A1 Tropoelastin-based protoelastin biomaterials |
| 04/03/2008 | WO2008022303A3 Anti-h5n1 influenza activity of the antiviral protein cyanovirin |
| 04/03/2008 | WO2008019143A3 Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition |
| 04/03/2008 | WO2008018792A3 Cyclic angiotensin analogs |
| 04/03/2008 | WO2008010088A3 Cd4 mimic peptides and their uses |
| 04/03/2008 | WO2008005470A9 Polypeptides that bind membrane proteins |
| 04/03/2008 | WO2008003863A3 Use of plant extracts as active slimming ingredients |
| 04/03/2008 | WO2007145672A3 Combinations of human proteins to enhance viability of stem cells and progenitor cells |
| 04/03/2008 | WO2007135182A3 Factor ix analogues having prolonged in vivo half life |
| 04/03/2008 | WO2007134908A3 Use of thymosin alpha 1 for the treatment of immunological diseases |
| 04/03/2008 | WO2007133778A3 Methods to restore glycemic control |
| 04/03/2008 | WO2007130302A3 Rage fusion proteins, formulations, and methods of use thereof |
| 04/03/2008 | WO2007128545A3 Mac30 gene |
| 04/03/2008 | WO2007127457A9 Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof |
| 04/03/2008 | WO2007126799A3 Compositions and methods of use for antibodies of c-met |
| 04/03/2008 | WO2007103515A3 Unstructured recombinant polymers and uses thereof |
| 04/03/2008 | WO2007101235A3 Improved antitumoral treatments |
| 04/03/2008 | WO2007100789A3 Gpat3 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase |
| 04/03/2008 | WO2007092165A3 Compositions and methods for enhancing neuronal plasticity and regeneration |
| 04/03/2008 | WO2007076032A3 Compositions and methods for producing a composition |
| 04/03/2008 | WO2007067683A3 Methods and compositions for expanding t regulatory cells |
| 04/03/2008 | WO2007059312A3 Methods and compositions comprising non-natural amino acids |
| 04/03/2008 | WO2006094093A3 A method for identifying skin care composition-resistant skin-binding peptides |
| 04/03/2008 | US20080082038 medical equipment comprising substrates having surface coatings selected from microbocidesl, antiseptics, anesthetics and anticoagulants; drug elution |
| 04/03/2008 | US20080081901 Alpha-conotoxin peptides |
| 04/03/2008 | US20080081831 (3mercapta-1,2,4-triazole-5yl)-phenyl-tertbutane; cadherin cell adhesion recognition sequence His-Ala-Val within a cyclic peptide ring; enhance drug delivery to cells in need (tumor, Schwann cells, oligodendrocytes, graft rejection, epidermal patches); anticarcinogenic, angiogenesis inhibitor |
| 04/03/2008 | US20080081813 Lipid Lowering Biphenylcarboxamides |
| 04/03/2008 | US20080081795 Suppression of nuclear factor-kappaB dependent processes using oligonucleotides |
| 04/03/2008 | US20080081793 Oligonucleotide Compositions and Their Use to Induce Apoptosis |
| 04/03/2008 | US20080081792 Expression vector comprising therapeutic RNA sequences for use in treatment and prevention of infection, viral diseases and cell proliferative disorders, tumor or cancer; antisense agents; gene expression inhibition |
| 04/03/2008 | US20080081789 Beta peptoids with antimicrobial activity |
| 04/03/2008 | US20080081788 reduce the elevated level of free IgE in patient's serum by oral administering peptide biodrug; also can reduce nerve growth factor, myoglobin, Insulin, adenosine deaminase; treating asthma, type 2 diabetes, depression, autoimmune diseases, diabetes, Graves' disease, Addison's disease, Hodgkin's disease |
| 04/03/2008 | US20080081787 stable aqueous solution containing endogenous growth hormone secretagogues having pH range of 2 to 7; a pH adjuster or a buffer agent; nondegradation, storage stability; biodrug inducing the secretion of growth hormone |
| 04/03/2008 | US20080081786 Cytokine protein family |
| 04/03/2008 | US20080081785 Paralytic Peptide For Use In Neuromuscular Therapy |
| 04/03/2008 | US20080081784 Administering to the cell a peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent for reducing wrinkles; inhibits calcium uptake |
| 04/03/2008 | US20080081783 Utilizing amino acid sequences linked to polyethylene glycol as agonists; increasing red blood cell production; chronic kidney disease |
| 04/03/2008 | US20080081782 Method for the selective enrichment and labeling of phosphorproteins |